Loading…

Carlsmed, Inc.CARLCompetitor analysis, valuation and peers

United States · USD·Information Technology›Information Technology Services
Momentum leader 92
Mkt cap
$476M
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$2.73M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-196.4 pp
WACC 14.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$17.37
1D-2.1%
1W-6.6%
1M+22.5%
3M+5.3%
6M+47.6%
YTD+40.6%
1Y+41.1%
ATR %7.6%
Beta1.65
52w lowhigh9.3% off high

What Carlsmed does

Employees: 127

Carlsmed at a glance

Size Carlsmed (CARL) is a United States Information Technology company (Information Technology Services) with a market value of $476M, the 2706th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.37 on 18 Nov 2026.

Performance Over six months the shares gained 47.6%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 60.4% over the last twelve months (peer median +4.6%); the operating margin is -55.0% (peer median 3.6%).

Valuation It trades at 5.8× enterprise value to sales against a peer median of 2.2× (6th most expensive of 20).

Capital Return on invested capital runs 196.4 points below its cost of capital (14.5% WACC).

Short interest Short interest is 4.5% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026CARL 137Peer median 80
Six months, rebased to 100: Carlsmed against the median of its 20 peers (local-currency closes).

Carlsmed financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$71.8M$50.5M$27.2M$13.8M
Revenue growth—+86%+97%—
Gross profit$55.2M$38.0M$20.0M$9.90M
EBITDA-$39.0M-$30.3M-$24.0M-$18.5M
Net income-$40.1M-$29.6M-$24.3M-$18.9M
Free cash flow-$34.9M-$29.6M-$25.6M-$17.6M
Capital expenditure$1.79M$1.36M$180,000$135,000
Total debt$21.8M$17.4M$17.2M$11.4M

Quarterly statements and history in the cockpit →

Carlsmed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%+20%MASTEK0024743011784674HSN3002313009629247NTGRRMNI3004486002894828CD605398YB300096ALC002331CARL6-month return →1-month return →
Up and to the right = strong over both horizons. Carlsmed is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×100×200×MASTEK0024743011784674300448600289CDCARLRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Carlsmed is the large dot.

Carlsmed competitors and peer comparison

How Carlsmed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Carlsmed against its 20 peers (data as of 18 Nov 2026)
MeasureCARLPeer medianRank in peer set
1-month return+22.5%-8.9%2nd highest of 21
6-month return+47.6%-20.3%2nd highest of 21
Distance from 52-week high-9.3%-38.2%2nd highest of 21
Revenue growth (TTM)+60.4%+4.6%4th highest of 21
Operating margin-55.0%3.6%2nd lowest of 20
EV / Sales5.8×2.2×6th most expensive of 20
ROIC minus cost of capital-196.4 pp-4.0 pplowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Carlsmed CARLUnited States$476M+48%+60%-55%5.8×n/an/a
Mastek MASTEK.NSIndia$479M-13%+6%13%1.0×6.3%+16.5%
Fujian Rongji Software 002474.SZChina$480M-35%-22%-21%9.6×30.0%-8.1%
Guangdong TianYiMa Information Industry 301178.SZChina$484M-4%+100%1%5.5×38.2%+5.5%
CRESCO 4674.TJapan$467M+22%+12%10%0.9×-1.5%+10.2%
Hansen Technologies HSN.AXAustralia$487M-24%-2%17%2.0×0.7%+4.7%
Beijing Trustfar Technology 300231.SZChina$464M-31%-2%4%1.8×11.3%-4.3%
Zhongjin Irradiation 300962.SZChina$493M-8%+1%27%8.6×n/an/a
Tre 9247.TJapan$459M-10%-11%11%0.9×-9.7%+23.2%
NETGEAR NTGRUnited States$497M-23%-3%-4%0.4×n/an/a
Rimini Street RMNIUnited States$501M+48%+3%7%1.1×12.0%+5.2%
Haoyun Technologies 300448.SZChina$453M-42%-52%n/a11.8×0.3%-12.8%
Brilliance Technology 300542.SZChina$450M-34%-20%1%3.0×n/an/a
Bright Oceans Inter-Telecom 600289.SSChina$447M-26%+231%-36%2.6×n/an/a
Business Engineering 4828.TJapan$445M+3%+12%27%2.2×-7.6%+6.7%
Chaince Digital CDUnited States$442M-56%+278%-177%212.0×n/an/a
Shanghai New Centurion Network Information Technology 605398.SSChina$514M-16%+15%-3%4.4×n/an/a
Yuanbao, Inc. Unsponsored ADR YBUnited States$516M-22%+37%32%n/an/an/a
YLZ Information Technology 300096.SZChina$516M-13%+3%-6%6.3×n/an/a
Altia Consultores ALC.MCSpain$438M-19%+19%8%1.2×-4.4%+19.4%
Anhui Wantong Technology 002331.SZChina$522M-27%+10%-17%2.0×18.4%-3.1%

Questions

Which companies are Carlsmed's closest peers?
The cockpit's peer set: Mastek (MASTEK.NS), Fujian Rongji Software (002474.SZ), Guangdong TianYiMa Information Industry (301178.SZ), CRESCO (4674.T), Hansen Technologies (HSN.AX), Beijing Trustfar Technology (300231.SZ), Zhongjin Irradiation (300962.SZ), Tre (9247.T).
Is Carlsmed expensive compared with its peers?
On ev / sales it trades at 5.8× against a peer median of 2.2×, 6th most expensive of 20 in its peer set.
How has Carlsmed stock performed?
Over six months to 18 Nov 2026 the shares returned +47.6% against -20.3% for the median peer; over one year +41.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.